Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway

Sang Soo Cho, Leigh Christopher, Yuko Koshimori, Crystal Li, Anthony E. Lang, Sylvain Houle, Antonio P. Strafella

Research output: Contribution to journalArticle

Abstract

To date, the contribution of the nigropallidal pathway degeneration to Parkinson's disease (PD) motor symptoms has received little attention and is generally poorly understood in spite of solid evidence that the globus pallidus (GP) receives a dense neuronal projection from the substantia nigra. To explore the dopaminergic (DA) changes of the GP in PD, we measured the availability of vesicular monoamine transporter 2 (VMAT2) using [11C]DTBZ and positron emission tomography in 30 PD patients and 12 controls. PD patients were classified in two groups based on severity of disease. VMAT2 reduction was found to be significant in the external GP (GPe) regardless of the disease stage, while the internal GP (GPi) showed reduction only in more severe patients. Pallidal VMAT2 binding correlated with dopaminergic changes in the striatum, with the GPe showing a stronger association than GPi. Our findings showed DA terminals in the GPe and GPi may be differentially vulnerable in different stages of the disease, possibly playing a distinctive role in the development of motor complications with GPi DA deficiency contributing more to later-stage symptoms.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalNeurobiology of Disease
Volume124
DOIs
StatePublished - Apr 2019
Externally publishedYes

Fingerprint

Vesicular Monoamine Transport Proteins
Globus Pallidus
Parkinson Disease
Substantia Nigra
Positron-Emission Tomography

Keywords

  • Dopamine
  • Globus pallidus
  • Parkinson's disease
  • Positron emission tomography
  • Vesicular monoamine transporter type 2

ASJC Scopus subject areas

  • Neurology

Cite this

Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease : The contribution of the nigropallidal pathway. / Cho, Sang Soo; Christopher, Leigh; Koshimori, Yuko; Li, Crystal; Lang, Anthony E.; Houle, Sylvain; Strafella, Antonio P.

In: Neurobiology of Disease, Vol. 124, 04.2019, p. 176-182.

Research output: Contribution to journalArticle

Cho, Sang Soo ; Christopher, Leigh ; Koshimori, Yuko ; Li, Crystal ; Lang, Anthony E. ; Houle, Sylvain ; Strafella, Antonio P. / Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease : The contribution of the nigropallidal pathway. In: Neurobiology of Disease. 2019 ; Vol. 124. pp. 176-182.
@article{1acb9e5c8bf645609840add44728b773,
title = "Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway",
abstract = "To date, the contribution of the nigropallidal pathway degeneration to Parkinson's disease (PD) motor symptoms has received little attention and is generally poorly understood in spite of solid evidence that the globus pallidus (GP) receives a dense neuronal projection from the substantia nigra. To explore the dopaminergic (DA) changes of the GP in PD, we measured the availability of vesicular monoamine transporter 2 (VMAT2) using [11C]DTBZ and positron emission tomography in 30 PD patients and 12 controls. PD patients were classified in two groups based on severity of disease. VMAT2 reduction was found to be significant in the external GP (GPe) regardless of the disease stage, while the internal GP (GPi) showed reduction only in more severe patients. Pallidal VMAT2 binding correlated with dopaminergic changes in the striatum, with the GPe showing a stronger association than GPi. Our findings showed DA terminals in the GPe and GPi may be differentially vulnerable in different stages of the disease, possibly playing a distinctive role in the development of motor complications with GPi DA deficiency contributing more to later-stage symptoms.",
keywords = "Dopamine, Globus pallidus, Parkinson's disease, Positron emission tomography, Vesicular monoamine transporter type 2",
author = "Cho, {Sang Soo} and Leigh Christopher and Yuko Koshimori and Crystal Li and Lang, {Anthony E.} and Sylvain Houle and Strafella, {Antonio P.}",
year = "2019",
month = "4",
doi = "10.1016/j.nbd.2018.11.022",
language = "English (US)",
volume = "124",
pages = "176--182",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease

T2 - The contribution of the nigropallidal pathway

AU - Cho, Sang Soo

AU - Christopher, Leigh

AU - Koshimori, Yuko

AU - Li, Crystal

AU - Lang, Anthony E.

AU - Houle, Sylvain

AU - Strafella, Antonio P.

PY - 2019/4

Y1 - 2019/4

N2 - To date, the contribution of the nigropallidal pathway degeneration to Parkinson's disease (PD) motor symptoms has received little attention and is generally poorly understood in spite of solid evidence that the globus pallidus (GP) receives a dense neuronal projection from the substantia nigra. To explore the dopaminergic (DA) changes of the GP in PD, we measured the availability of vesicular monoamine transporter 2 (VMAT2) using [11C]DTBZ and positron emission tomography in 30 PD patients and 12 controls. PD patients were classified in two groups based on severity of disease. VMAT2 reduction was found to be significant in the external GP (GPe) regardless of the disease stage, while the internal GP (GPi) showed reduction only in more severe patients. Pallidal VMAT2 binding correlated with dopaminergic changes in the striatum, with the GPe showing a stronger association than GPi. Our findings showed DA terminals in the GPe and GPi may be differentially vulnerable in different stages of the disease, possibly playing a distinctive role in the development of motor complications with GPi DA deficiency contributing more to later-stage symptoms.

AB - To date, the contribution of the nigropallidal pathway degeneration to Parkinson's disease (PD) motor symptoms has received little attention and is generally poorly understood in spite of solid evidence that the globus pallidus (GP) receives a dense neuronal projection from the substantia nigra. To explore the dopaminergic (DA) changes of the GP in PD, we measured the availability of vesicular monoamine transporter 2 (VMAT2) using [11C]DTBZ and positron emission tomography in 30 PD patients and 12 controls. PD patients were classified in two groups based on severity of disease. VMAT2 reduction was found to be significant in the external GP (GPe) regardless of the disease stage, while the internal GP (GPi) showed reduction only in more severe patients. Pallidal VMAT2 binding correlated with dopaminergic changes in the striatum, with the GPe showing a stronger association than GPi. Our findings showed DA terminals in the GPe and GPi may be differentially vulnerable in different stages of the disease, possibly playing a distinctive role in the development of motor complications with GPi DA deficiency contributing more to later-stage symptoms.

KW - Dopamine

KW - Globus pallidus

KW - Parkinson's disease

KW - Positron emission tomography

KW - Vesicular monoamine transporter type 2

UR - http://www.scopus.com/inward/record.url?scp=85057089649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057089649&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2018.11.022

DO - 10.1016/j.nbd.2018.11.022

M3 - Article

C2 - 30471418

AN - SCOPUS:85057089649

VL - 124

SP - 176

EP - 182

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -